A novel proof-of-concept study assessing the lightening effects and safety of malassezin for treatment of facial hyperpigmentation
J Am Acad Dermatol
.
2022 Aug;87(2):456-458.
doi: 10.1016/j.jaad.2021.10.008.
Epub 2021 Oct 19.
Authors
Pearl E Grimes
1
,
Jag Bhawan
2
,
Michael D Howell
3
,
Seemal Desai
4
,
Edna Coryell
5
,
Rama Nashawati
6
,
Michael Einziger
7
,
Ann Marie Simpson
7
,
Alex Yaroshinsky
8
,
Tim Mc Craw
5
Affiliations
1
Vitiligo & Pigmentation Institute of Southern California, Los Angeles, California. Electronic address: adminassistant@pearlgrimesmd.com.
2
Department of Dermatopathology, Boston University, Massachusetts.
3
DermTech, La Jolla, California.
4
Innovative Dermatology, Plano, Texas; Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas.
5
Skin Science Advisors LLC, Pacolet, South Carolina.
6
Vitiligo & Pigmentation Institute of Southern California, Los Angeles, California.
7
Versicolor Technologies LLC, Santa Monica, California.
8
Vital Systems Incorporated, Rolling Meadows, Illinois.
PMID:
34678236
DOI:
10.1016/j.jaad.2021.10.008
No abstract available
Publication types
Research Support, Non-U.S. Gov't
MeSH terms
Humans
Hyperpigmentation* / drug therapy
Indoles
Skin Lightening Preparations*
Substances
Indoles
Skin Lightening Preparations
malassezin